COT Programs
Our team has rigorous guidelines in place to protect the well-being and safety of clinical trial participants, who are, of course, always fully aware of their participation. This research is carried out in collaboration with Greek and international academic and research institutions and usually results in publication of research papers in peer review journals.
CA209-651: An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic.
HE 37/12: Clinical trial phase II single-arm administration of pazopanib with gemcitabine as first-line treatment in patients with unresectable locally advanced or metastatic biliary tree cancer (cholangiocarcinoma and gallbladder carcinoma).
MELPOMENI: Safety and efficacy of RAD001 (everolimus) administered in relapse during or after adjuvant therapy in postmenopausal women and hormone receptor positive, HER2/neu negative (HR + HER2-) in locally advanced or metastatic breast cancer.